Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers
- Sponsor
- European Institute of Oncology
- Study ID
- NCT07815873
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Cervical Cancer
- Endometrial Cancer
- Melanoma (Skin Cancer)
- Non Small Cell Lung Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- sample collection — BIOLOGICALClinical and radiological assessment will be performed at the enrollment and every 3 +/- 1 months. Clinical information and biological samples will be collected also at 2 years from surgery or start of therapy. We plan collection of a maximum of 13 faecal and blood samples per patient (1 baseline + a maximum of 11 during treatment ± 1 disease progression, ± 10%). In addition, we expect to collect fresh stools and tissue biopsies from at least 3-5 patients per group every year, which will be dedicated to our translational studies.
Study Details
This study aims to investigate the role of the gut microbiota and its derived factors, including bacterial-associated antigens that mimic tumor-associated antigens, in predicting response to immune checkpoint inhibitor immunotherapies in patients with various types of cancer. The aim is to explore whether gut microbiota-mediated immunological modulation is specific to the tumor being treated and whether it can be used to enhance antitumor response.
Key Dates
- First listed
- Sep 11, 2026
- Start date
- Oct 1, 2026
- Status verified
- Jul 2026
- Primary completion
- Oct 1, 2027
- Completion
- Apr 1, 2031
Study Design
- Enrollment
- 360 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Biological Sample collectionBiological Sample
Primary Outcome Measure
Primary Endopoint [ Time Frame: 1 year ]
Central Contacts
- Luigi Nezi, PhD+39 02 94375171
- Giulia Sedda, PhD
Find similar trials
Related Studies
- Specimen and Data Study for Ovarian Cancer Early Detection and PreventionRecruiting · Northwestern University · Chicago, Illinois
- The Effect of Beta-glucan in Non-Small Cell Lung CancerRecruiting · University of Louisville · Louisville, Kentucky
- Cervical Cancer Detection Using Optical SpectroscopyRecruiting · Duke University · Durham, North Carolina
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado